Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix Extension Study in Prostate Cancer
NCT00245466Phase 2Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2001
- Primary completion
- Mar 2006
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Liver Function Tests at 3 years and Participants With Markedly Abnormal Change in Vital Signs and Body Weight at 3 years. Started Oct 2001; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00245466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245466.